Improvement in Patients with PsA at Week 16 in FUTURE Trialsa
Select PsA Core DomainsMeasures and Improvement DefinitionsSecukinumab 300 mg, n = 461Secukinumab 150 mg, n = 572Secukinumab 150 mg No Load, n = 335Placebo, n = 681
PainPsA pain, mean change from BL (SE)b,c−19.75 (1.11), n = 440−15.94 (0.98), n = 545−15.44 (1.32), n = 320−4.46 (0.93), n = 616
PtGAPatient global assessment, mean change from BL (SE)b,c−20.04 (1.11), n = 440−15.92 (0.98), n = 545−14.60 (1.33), n = 320−5.31 (0.93), n = 616
Physical functionHAQ-DI, mean change from BL (SE)b−0.48 (0.02), n = 438−0.36 (0.02), n = 544−0.40 (0.03), n = 320−0.16 (0.02), n = 615
HRQOLPsAQOL, mean change from BLb−3.65, n = 443−3.26, n = 548−3.16, n = 319−1.20, n = 622
DLQI, mean change from BLb,c−7.11, n = 273−6.57, n = 166−6.29, n = 339−2.14, n = 356
FatigueFACIT-Fatigue, mean change from BLb,c6.21, n = 4425.26, n = 5465.42, n = 3191.79, n = 621
Improvement in Patients with Ankylosing Spondylitis at Week 16 in MEASURE 2a,d
Secukinumab 150 mg, n = 72Placebo, n = 74
Spine symptomsBASDAI, mean change from BL (SD)−2.19 (0.25)−0.85 (0.25)
  • a All p values vs placebo were p < 0.05. All p values were for hypothesis generation. No adjustment was made for multiple comparisons.

  • b Least squares mean change from BL; n is the number of patients with measures at both BL and Week 16 visit.

  • c No MCID has been defined in PsA.

  • d Baeten D, et al. N Engl J Med 2015;373:2534-48. BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BL: baseline; DLQI: Dermatology Life Quality Index; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy–Fatigue scale; GRAPPA: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; HAQ-DI: Health Assessment Questionnaire–Disability Index; HRQOL: health-related quality of life; OMERACT: Outcome Measures in Rheumatology; PsA: psoriatic arthritis; PsAQOL: PsA-specific quality of life; PtGA: patient’s global assessment; SE: standard error; MCID: minimal clinically important difference.